Ailanthone: A novel potential drug for treating human cancer (Review)
- Authors:
- Haixiang Ding
- Xiuchong Yu
- Chen Hang
- Kaijun Gao
- Xifeng Lao
- Yangtao Jia
- Zhilong Yan
-
Affiliations: Medical School of Ningbo University, Ningbo University, Ningbo, Zhejiang 315211, P.R. China, Department of Gastrointestinal Surgery, The Affiliated Hospital of The Medical School of Ningbo University and Ningbo First Hospital, Ningbo, Zhejiang 315010, P.R. China - Published online on: June 9, 2020 https://doi.org/10.3892/ol.2020.11710
- Pages: 1489-1503
-
Copyright: © Ding et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Blattner WA: Human retroviruses: Their role in cancer. Proc Assoc Am Physicians. 111:563–572. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Tomlinson IP, Novelli MR and Bodmer WF: The mutation rate and cancer. Proc Natl Acad Sci USA. 93:14800–14803. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Wogan GN, Hecht SS, Felton JS, Conney AH and Loeb LA: Environmental and chemical carcinogenesis. Semin Cancer Biol. 14:473–486. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chen W, Zheng R, Zhang S, Zhang S, Zeng H, Xia C, Zuo T, Yang Z, Zou X and He J: Cancer incidence and mortality in China, 2013. Cancer Lett. 401:63–71. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Tseng HH and He B: Molecular markers as therapeutic targets in lung cancer. Chin J Cancer. 32:59–62. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Qi F, Zhao L, Zhou A, Zhang B, Li A, Wang Z and Han J: The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer. Biosci Trends. 9:16–34. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Nakamura K, Shinozuka K and Yoshikawa N: Anticancer and antimetastatic effects of cordycepin, an active component of cordyceps sinensis. J Pharmacol Sci. 127:53–56. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lumlerdkij N, Tantiwongse J, Booranasubkajorn S, Boonrak R, Akarasereenont P, Laohapand T and Heinrich M: Understanding cancer and its treatment in thai traditional medicine: An ethnopharmacological-anthropological investigation. J Ethnopharmacol. 216:259–273. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Bezwoda WR, MacDonald DF, Gear JS, Derman DP, Bothwell TH, Sqi S, Hurwitz S and Lewis D: Combination chemotherapy including bleomycin in the treatment of advanced hodgkin's disease. S Afr Med J. 53:369–373. 1978.PubMed/NCBI | |
|
Durant JR, Gams RA, Bartolucci AA and Dorfman RF: BCNU with and without cyclophosphamide, vincristine, and prednisone (COP) and cycle-active therapy in non-hodgkin's lymphoma. Cancer Treat Rep. 61:1085–1096. 1977.PubMed/NCBI | |
|
Wong MY and Chiu GN: Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model. Nanomedicine. 7:834–840. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Munker S, Vogelhuber M, Bornschein J, Stroszczynski C, Evert M, Schlitt H, Herr W and Teufel A: EpiCO (epirubicin, cyclophosphamide and vincristine) as treatment for extrapulmonary high-grade neuroendocrine neoplasms. Z Gastroenterol. 58:133–136. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Büyükkapu Bay S, Kebudi R, Görgün O, Zülfikar B, Darendeliler E and Çakır FB: Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience. J Oncol Pharm Pract. 25:1343–1348. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Weaver BA: How taxol/paclitaxel kills cancer cells. Mol Biol Cell. 25:2677–2681. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Caparica R, Bruzzone M, Poggio F, Ceppi M, de Azambuja E and Lambertini M: Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: A systematic review and meta-analysis of randomized controlled trials. Breast Cancer Res Treat. 174:27–37. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Reck M, Brahmer J, Bennett B, Taylor F, Penrod JR, DeRosa M, Dastani H, Spigel DR and Gralla RJ: Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in checkmate 057. Eur J Cancer. 102:23–30. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
da Rocha AB, Lopes RM and Schwartsmann G: Natural products in anticancer therapy. Curr Opin Pharmacol. 1:364–369. 2001. View Article : Google Scholar | |
|
Wang P, Yang HL, Yang YJ, Wang L and Lee SC: Overcome cancer cell drug resistance using natural products. Evid Based Complement Alternat Med. 2015:7671362015. View Article : Google Scholar : PubMed/NCBI | |
|
Wu X, Kong W, Qi X, Wang S, Chen Y, Zhao Z, Wang W, Lin X, Lai J, Yu Z and Lai G: Icariin induces apoptosis of human lung adenocarcinoma cells by activating the mitochondrial apoptotic pathway. Life Sci. 15:1168792019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang P, Zhang M, Yu D, Liu W, Hu L, Zhang B, Zhou Q and Cao Z: Lycorine inhibits melanoma cell migration and metastasis mainly through reducing intracellular levels of beta-catenin and matrix metallopeptidase 9. J Cell Physiol. 234:10566–10575. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Segun PA, Ismail FMD, Ogbole OO, Nahar L, Evans AR, Ajaiyeoba O and Sarker SD: Acridone alkaloids from the stem bark of citrus aurantium display selective cytotoxicity against breast, liver, lung and prostate human carcinoma cells. J Ethnopharmacol. 227:131–138. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Tomar P, Dey YN, Sharma D, Wanjari MM, Gaidhani S and Jadhav A: Cytotoxic and antiproliferative activity of kanchnar guggulu, an ayurvedic formulation. J Integr Med. 16:411–417. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Dhiman K: Ayurvedic intervention in the management of uterine fibroids: A case series. Ayu. 35:303–308. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kasymjanova G, Tran AT, Cohen V, Pepe C, Sakr L, Small D, Agulnik JS and Jagoe RT: The use of a standardized Chinese herbal formula in patients with advanced lung cancer: A feasibility study. J Integr Med. 16:390–395. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang R, Lu Y, Li H, Sun L, Yang N, Zhao M, Zhang M and Shi Q: Antitumor activity of the ailanthus altissima bark phytochemical ailanthone against breast cancer MCF-7 cells. Oncol Lett. 15:6022–6028. 2018.PubMed/NCBI | |
|
Rahman S, Fukamiya N, Ohno N, Tokuda H, Nishino H, Tagahara, Lee KH and Okano M: Inhibitory effects of quassinoid derivatives on epstein-barr virus early antigen activation. Chem Pharm Bull (Tokyo). 45:675–677. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Cho SK, Jeong M, Jang DS and Choi JH: Anti-Inflammatory effects of canthin-6-one alkaloids from ailanthus altissima. Planta Med. 84:527–535. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Okunade AL, Bikoff RE, Casper SJ, Oksman A, Goldberg DE and Lewis WH: Antiplasmodial activity of extracts and quassinoids isolated from seedlings of ailanthus altissima (Simaroubaceae). Phytother Res. 17:675–677. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Jin M, Yang JH, Lee E, Lu Y, Kwon S, Son KH, Son KH, Son JK and Chang HW: Antiasthmatic activity of luteolin-7-O-glucoside from Ailanthus altissima through the downregulation of T helper 2 cytokine expression and inhibition of prostaglandin E2 production in an ovalbumin-induced asthma model. Biol Pharm Bull. 32:1500–1503. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Rahman S, Fukamiya N, Okano M, Tagahara K and Lee KH: Anti-Tuberculosis activity of quassinoids. Chem Pharm Bull (Tokyo). 45:1527–1529. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Melanchauski LS, Broto AP, Moraes TM, Nasser ALM, Said A, Hawas UW, Rashed K, Vilegas W and Hiruma-Lima CA: Gastroprotective and antisecretory effects of ailanthus excelsa (Roxb). J Nat Med. 64:109–113. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Wright CW, O'Neill MJ, Phillipson JD and Warhurst DC: Use of microdilution to assess in vitro antiamoebic activities of brucea javanica fruits, simarouba amara stem, and a number of quassinoids. Antimicrob Agents Chemother. 32:1725–1729. 1988. View Article : Google Scholar : PubMed/NCBI | |
|
Kundu P and Laskar S: A brief resume on the genus Ailanthus: Chemical and pharmacological aspects. Phytochem Rev. 9:379–412. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kato T, Suzumura Y, Fukushima M, Honda T, Nakanishi T and Noguchi T: Antitumor activity of novel ailanthone derivatives in vitro and in vivo. Anticancer Res. 8:573–579. 1988.PubMed/NCBI | |
|
Liu W, Liu X, Pan Z, Wang D, Li M, Chen X, Zhou L, Xu M, Li D and Zheng Q: Ailanthone induces cell cycle arrest and apoptosis in melanoma B16 and A375 cells. Biomolecules. 9:2752019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Zhang C and Min D: Ailanthone up-regulates miR-449a to restrain acute myeloid leukemia cells growth, migration and invasion. Exp Mol Pathol. 108:114–120. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wei C, Chen C, Cheng Y, Zhu L, Wang Y, Luo C, He Y, Yang Z and Ji Z: Ailanthone induces autophagic and apoptotic cell death in human promyelocytic leukemia HL-60 cells. Oncol Lett. 16:3569–3576. 2018.PubMed/NCBI | |
|
Daga M, Pizzimenti S, Dianzani C, Cucci MA, Cavalli R, Grattarola M, Ferrara B, Scariot V, Trotta F and Barrera G: Ailanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expression. Phytomedicine. 56:156–164. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hou S, Cheng Z, Wang W, Wang X and Wu Y: Ailanthone exerts an antitumor function on the development of human lung cancer by upregulating microRNA-195. J Cell Biochem. 120:10444–10451. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ni Z, Yao C, Zhu X, Gong C, Xu Z, Wang L, Li S, Zou C and Zhu S: Ailanthone inhibits non-small cell lung cancer cell growth through repressing DNA replication via downregulating RPA1. Br J Cancer. 117:1621–1630. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Y, Zhu L, Yang X, Wei C, Chen C, He Y and Ji Z: Ailanthone induces G2/M cell cycle arrest and apoptosis of SGC7901 human gastric cancer cells. Mol Med Rep. 16:6821–6827. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhuo Z, Hu J, Yang X, Chen M, Lei X, Deng L, Yao N, Peng Q, Chen Z, Ye W and Zhang D: Ailanthone inhibits huh7 cancer cell growth via cell cycle arrest and apoptosis in vitro and in vivo. Sci Rep. 5:161852015. View Article : Google Scholar : PubMed/NCBI | |
|
Gao W, Ge S and Sun J: Ailanthone exerts anticancer effect by up-regulating miR-148a expression in MDA-MB-231 breast cancer cells and inhibiting proliferation, migration and invasion. Biomed Pharmacother. 109:1062–1069. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Yang P, Sun D and Jiang F: Ailanthone promotes human vestibular schwannoma cell apoptosis and autophagy by downregulation of miR-21. Oncol Res. 26:941–948. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kong D, Ying B, Zhang J and Ying H: The anti-osteosarcoma property of ailanthone through regulation of miR-126/VEGF-A axis. Artif Cells Nanomed Biotechnol. 47:3913–3919. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
He Y, Peng S, Wang J, Chen H, Cong X, Chen A, Hu M, Qin M, Wu H, Gao S, et al: Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer. Nat Commun. 7:131222016. View Article : Google Scholar : PubMed/NCBI | |
|
Han F, Liu G, Sun C and Wei J: Ailanthone reverses multidrug resistance by inhibiting the P-glycoprotein-mediated efflux in resistant K562/A02 cells. Cell Mol Biol (Noisy-le-grand). 64:55–61. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Guy GP Jr, Thomas CC, Thompson T, Watson M, Massetti GM and Richardson LC; Centers for Disease Control and Prevention (CDC), : Vital signs: Melanoma incidence and mortality trends and projections - United States, 1982-2030. MMWR Morb Mortal Wkly Rep. 64:591–596. 2015.PubMed/NCBI | |
|
Lens MB and Dawes M: Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol. 150:179–185. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Yamamoto JF and Goodman MT: Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control. 19:379–390. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Shin VY and Chu KM: miRNA as potential biomarkers and therapeutic targets for gastric cancer. World J Gastroenterol. 20:10432–10439. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chen YJ, Guo YN, Shi K, Huang HM, Huang SP, Xu WQ, Li ZY, Wei KL, Gan TQ and Chen G: Down-Regulation of microRNA-144-3p and its clinical value in non-small cell lung cancer: A comprehensive analysis based on microarray, miRNA-sequencing, and quantitative real-time PCR data. Respir Res. 20:482019. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan G, Zhao Y, Wu D, Gao C and Jiao Z: miRNA-20a upregulates TAK1 and increases proliferation in osteosarcoma cells. Future Oncol. 14:461–469. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
De Luca L, Trino S, Laurenzana I, Tagliaferri D, Falco G, Grieco V, Bianchino G, Nozza F, Campia V, D'Alessio F, et al: Knockdown of miR-128a induces Lin28a expression and reverts myeloid differentiation blockage in acute myeloid leukemia. Cell Death Dis. 8:e28492017. View Article : Google Scholar | |
|
Elhamamsy AR, El Sharkawy MS, Zanaty AF, Mahrous MA, Mohamed AE and Abushaaban EA: Circulating miR-92a, miR-143 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia. Int J Mol Cell Med. 6:77–86. 2017.PubMed/NCBI | |
|
Li Q, Peng J, Li X, Leng A and Liu T: MiR-449a targets Flot2 and inhibits gastric cancer invasion by inhibiting TGF-beta-mediated EMT. Diagn Pathol. 10:2022015. View Article : Google Scholar : PubMed/NCBI | |
|
Sandbothe M, Buurman R, Reich N, Greiwe L, Vajen B, Gürlevik E, Schäffer V, Eilers M, Kühnel F, Vaquero A, et al: The microRNA-449 family inhibits TGF-beta-mediated liver cancer cell migration by targeting SOX4. J Hepatol. 66:1012–1021. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
DeGeorge KC, Holt HR and Hodges SC: Bladder cancer: Diagnosis and treatment. Am Fam Physician. 96:507–514. 2017.PubMed/NCBI | |
|
Nadal R and Bellmunt J: Management of metastatic bladder cancer. Cancer Treat Rev. 76:10–21. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ciamporcero E, Daga M, Pizzimenti S, Roetto A, Dianzani C, Compagnone A, Palmieri A, Ullio C, Cangemi L, Pili R and Barrera G: Crosstalk between Nrf2 and YAP contributes to maintaining the antioxidant potential and chemoresistance in bladder cancer. Free Radic Biol Med. 115:447–457. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Rojo de la Vega M, Chapman E and Zhang DD: NRF2 and the hallmarks of cancer. Cancer Cell. 34:21–43. 2018. View Article : Google Scholar | |
|
Zanconato F, Cordenonsi M and Piccolo S: YAP/TAZ at the roots of cancer. Cancer Cell. 29:783–803. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Zhang X, Zou C, Kung HF, Lin MC, Dress A, Wardle F, Jiang BH and Lai L: miR-195 inhibits tumor growth and angiogenesis through modulating IRS1 in breast cancer. Biomed Pharmacother. 80:95–101. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Liu B, Qu J, Xu F, Guo Y, Wang Y, Yu H and Qian B: miR-195 suppresses non-small cell lung cancer by targeting CHEK1. Oncotarget. 6:9445–9456. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yu S, Jing L, Yin XR, Wang MC, Chen YM, Guo Y, Nan KJ and Han LL: miR-195 suppresses the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by inhibiting YAP. Oncotarget. 8:99757–99771. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Tao T, Liu C, Guan H, Huang Y, Xu B and Chen M: Downregulation of miR-195 promotes prostate cancer progression by targeting HMGA1. Oncol Rep. 36:376–382. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Brackmann DE: Vestibular schwannoma (acoustic neuroma). Otolaryngol Clin North Am. 45:xiii–xv. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Rosahl S, Bohr C, Lell M, Hamm K and Iro H: Diagnosis and management of vestibular schwannomas - an interdisciplinary challenge. Laryngorhinootologie. 96:S152–S182. 2017.(In German). PubMed/NCBI | |
|
Feng YH, Wu CL, Tsao CJ, Chang JG, Lu PJ, Yeh KT, Uen YH, Lee JC and Shiau AL: Deregulated expression of sprouty2 and microRNA-21 in human colon cancer: Correlation with the clinical stage of the disease. Cancer Biol Ther. 11:111–121. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wu X, Zhuo S, Zheng C and Gao G: MicroRNA-21 correlates TGF-beta1 pathway of pancreatic ductal adenocarcinoma. Zhong Nan Da Xue Xue Bao. 44:749–756. 2019.(In Chinese). PubMed/NCBI | |
|
Bharali D, Banerjee BD, Bharadwaj M, Husain SA and Kar P: Expression analysis of microrna-21 and microrna-122 in hepatocellular carcinoma. J Clin Exp Hepatol. 9:294–301. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Mirabello L, Troisi RJ and Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the surveillance, epidemiology, and end results program. Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Harrison DJ, Geller DS, Gill JD, Lewis VO and Gorlick R: Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther. 18:39–50. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kim YH, Goh TS, Lee CS, Oh SO, Kim JI, Jeung SH and Pak K: Prognostic value of microRNAs in osteosarcoma: A meta-analysis. Oncotarget. 8:8726–8737. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Hesse E and Taipaleenmaki H: MicroRNAs in bone metastasis. Curr Osteoporos Rep. 17:122–128. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sasaki R, Osaki M and Okada F: MicroRNA-Based diagnosis and treatment of metastatic human osteosarcoma. Cancers. 11:5532019. View Article : Google Scholar : PubMed/NCBI | |
|
Huggins C and Hodges CV: Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 22:232–240. 1972. View Article : Google Scholar : PubMed/NCBI | |
|
Koochekpour S: Androgen receptor signaling and mutations in prostate cancer. Asian J Androl. 12:639–657. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Harris WP, Mostaghel EA, Nelson PS and Montgomery B: Androgen deprivation therapy: Progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 6:76–85. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 351:1513–1520. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet. 376:1147–1154. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, et al: Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 16:152–160. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, et al: Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 369:213–223. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, et al: Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 371:424–433. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, et al: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 367:1187–1197. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, et al: AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 371:1028–1038. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Cano LQ, Lavery DN and Bevan CL: Mini-Review: Foldosome regulation of androgen receptor action in prostate cancer. Mol Cell Endocrinol. 369:52–62. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Tao WW, Jiang H, Tao XM, Jiang P, Sha LY and Sun XC: Effects of acupuncture, tuina, tai chi, qigong, and traditional Chinese medicine five-element music therapy on symptom management and quality of life for cancer patients: A meta-analysis. J Pain Symptom Manage. 51:728–747. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Tang S, Ma X, Lu J, Zhang Y, Liu M and Wang X: Preclinical toxicology and toxicokinetic evaluation of ailanthone, a natural product against castration-resistant prostate cancer, in mice. Fitoterapia. 136:1041612019. View Article : Google Scholar : PubMed/NCBI | |
|
Winder C, Azzi R and Wagner D: The development of the globally harmonized system (GHS) of classification and labelling of hazardous chemicals. J Hazard Mater. 125:29–44. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Hassan M, Watari H, AbuAlmaaty A, Ohba Y and Sakuragi N: Apoptosis and molecular targeting therapy in cancer. BioMed Res Int. 2014:1508452014. View Article : Google Scholar : PubMed/NCBI | |
|
Goldar S, Khaniani MS, Derakhshan SM and Baradaran B: Molecular mechanisms of apoptosis and roles in cancer development and treatment. Asian Pac J Cancer Prev. 16:2129–2144. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Green DR and Reed JC: Mitochondria and apoptosis. Science. 281:1309–1312. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Redza-Dutordoir M and Averill-Bates DA: Activation of apoptosis signalling pathways by reactive oxygen species. Biochim Biophys Acta. 1863:2977–2992. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Cory S, Roberts AW, Colman PM and Adams JM: Targeting BCL-2-like proteins to kill cancer cells. Trends Cancer. 2:443–460. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lowe SW, Schmitt EM, Smith SW, Osborne BA and Jacks T: P53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 362:847–849. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Kastenhuber ER and Lowe SW: Putting p53 in context. Cell. 170:1062–1078. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z, Wang N, Liu P and Xie X: AMPK and cancer. Exp Suppl. 107:203–226. 2016.PubMed/NCBI | |
|
Aziz SA, Jilaveanu LB, Zito C, Camp RL, Rimm DL, Conrad P and Kluger HM: Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clin Cancer Res. 16:6029–6039. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Brachmann SM, Hofmann I, Schnell C, Fritsch C, Wee S, Lane H, Wang S, Echeverria CG and Maira SM: Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci USA. 106:22299–22304. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Martinelli E, Troiani T, D'Aiuto E, Morgillo F, Vitagliano D, Capasso A, Costantino S, Ciuffreda LP, Merolla F, Vecchione L, et al: Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. Int J Cancer. 133:2089–2101. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lim HJ, Crowe P and Yang JL: Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer. J Cancer Res Clin Oncol. 141:671–689. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hassan B, Akcakanat A, Holder AM and Meric-Bernstam F: Targeting the PI3-kinase/Akt/mTOR signaling pathway. Surg Oncol Clin N Am. 22:641–664. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Panda M and Biswal BK: Cell signaling and cancer: A mechanistic insight into drug resistance. Mol Biol Rep. 46:5645–5659. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmäki H, Andersson EI, Lagström S, Clemente MJ, Olson T, Jalkanen SE, et al: Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 366:1905–1913. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Cocchiola R, Rubini E, Altieri F, Chichiarelli S, Paglia G, Romaniello D, Carissimi S, Giorgi A, Giamogante F, Macone A, et al: STAT3 post-translational modifications drive cellular signaling pathways in prostate cancer cells. Int J Mol Sci. 20:8152019. View Article : Google Scholar : PubMed/NCBI | |
|
Horiguchi A, Oya M, Shimada T, Uchida A, Marumo K and Murai M: Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: A study of incidence and its association with pathological features and clinical outcome. J Urol. 168:762–765. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu H, Chang LL, Yan FJ, Hu Y, Zeng CM, Zhou TY, Yuan T, Ying MD, Cao J, He QJ and Yang B: AKR1C1 activates STAT3 to promote the metastasis of non-small cell lung cancer. Theranostics. 8:676–692. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Nishimoto A, Kugimiya N, Hosoyama T, Enoki T, Li TS and Hamano K: JAB1 regulates unphosphorylated STAT3 DNA-binding activity through protein-protein interaction in human colon cancer cells. Biochem Biophy Res Commun. 438:513–518. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wei D, Le X, Zheng L, Wang L, Frey JA, Gao AC, Peng Z, Huang S, Xiong HQ, Abbruzzese JL and Xie K: Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene. 22:319–329. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Wu M, Song D, Li H, Yang Y, Ma X, Deng S, Ren C and Shu X: Negative regulators of STAT3 signaling pathway in cancers. Cancer Manag Res. 11:4957–4969. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, Willman CL and Radich JP: FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood. 97:3589–3595. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Polakis P: Wnt signaling in cancer. Cold Spring Harb Perspect Biol. 4:a0080522012. View Article : Google Scholar : PubMed/NCBI | |
|
Tan SH and Barker N: Wnt signaling in adult epithelial stem cells and cancer. Prog Mol Biol Transl Sci. 153:21–79. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Taketo MM: Shutting down wnt signal-activated cancer. Nat Genet. 36:320–322. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Radtke F and Raj K: The role of Notch in tumorigenesis: Oncogene or tumour suppressor? Nat Rev Cancer. 3:756–767. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Huang T, Zhou Y, Cheng AS, Yu J, To KF and Kang W: NOTCH receptors in gastric and other gastrointestinal cancers: Oncogenes or tumor suppressors? Mol Cancer. 15:802016. View Article : Google Scholar : PubMed/NCBI | |
|
Lobry C, Oh P, Mansour MR, Look AT and Aifantis I: Notch signaling: Switching an oncogene to a tumor suppressor. Blood. 123:2451–2459. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Xu X, Zhao Y, Xu M, Dai Q, Meng W, Yang J and Qin R: Activation of Notch signal pathway is associated with a poorer prognosis in acute myeloid leukemia. Med Oncol. 28:S483–S489. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Ono M, Takimoto R, Osuga T, Okagawa Y, Hirakawa M, Yoshida M, Arihara Y, Uemura N, Hayasaka N, Miura S, et al: Targeting notch-1 positive acute leukemia cells by novel fucose-bound liposomes carrying daunorubicin. Oncotarget. 7:38586–38597. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Johnson DG and Walker CL: Cyclins and cell cycle checkpoints. Ann Rev Pharmacol Toxicol. 39:295–312. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Vermeulen K, Van Bockstaele DR and Berneman ZN: The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 36:131–149. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Geng Y, Eaton EN, Picon M, Roberts JM, Lundberg AS, Gifford A, Sardet C and Weinberg RA: Regulation of cyclin E transcription by E2Fs and retinoblastoma protein. Oncogene. 12:1173–1180. 1996.PubMed/NCBI | |
|
Ohtani K, DeGregori J and Nevins JR: Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci USA. 92:12146–12150. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Luo Z, Zang M and Guo W: AMPK as a metabolic tumor suppressor: Control of metabolism and cell growth. Future Oncol. 6:457–470. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Galluzzi L, Bravo-San Pedro JM, Levine B, Green DR and Kroemer G: Pharmacological modulation of autophagy: Therapeutic potential and persisting obstacles. Nat Rev Drug Discov. 16:487–511. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Choi KS: Autophagy and cancer. Exp Mol Med. 44:109–120. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H and Levine B: Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature. 402:672–676. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Komatsu M, Waguri S, Koike M, Sou YS, Ueno T, Hara T, Mizushima N, Iwata JI, Ezaki J, Murata S, et al: Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell. 131:1149–1163. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Tanida I, Minematsu-Ikeguchi N, Ueno T and Kominami E: Lysosomal turnover, but not a cellular level, of endogenous LC3 is a marker for autophagy. Autophagy. 1:84–91. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Tanida I, Ueno T and Kominami E: LC3 and Autophagy. Methods Mol Biol. 445:77–88. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Mundade R, Imperiale TF, Prabhu L, Loehrer PJ and Lu T: Genetic pathways, prevention, and treatment of sporadic colorectal cancer. Oncoscience. 1:400–406. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Coleman MP: Cancer survival: Global surveillance will stimulate health policy and improve equity. Lancet. 383:564–573. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Winer A, Adams S and Mignatti P: Matrix metalloproteinase inhibitors in cancer therapy: Turning past failures into future successes. Mol Cancer Ther. 17:1147–1155. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Hung WC, Tseng WL, Shiea J and Chang HC: Skp2 overexpression increases the expression of MMP-2 and MMP-9 and invasion of lung cancer cells. Cancer Lett. 288:156–161. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Karthika C and Sureshkumar R: Can curcumin along with chemotherapeutic drug and lipid provide an effective treatment of metastatic colon cancer and alter multidrug resistance? Med Hypotheses. 132:1093252019. View Article : Google Scholar : PubMed/NCBI | |
|
An Q, Han C, Zhou Y, Li F, Li D, Zhang X, Yu Z, Duan Z and Kan Q: Matrine induces cell cycle arrest and apoptosis with recovery of the expression of miR-126 in the A549 non-small cell lung cancer cell line. Mol Med Rep. 14:4042–4048. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Bjorklund M, Roos J, Gogvadze V and Shoshan M: Resveratrol induces SIRT1- and energy-stress-independent inhibition of tumor cell regrowth after low-dose platinum treatment. Cancer Chemother Pharmacol. 68:1459–1467. 2011. View Article : Google Scholar : PubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBIPubMed/NCBI |
